Abstract:Mounting evidence underscores the intricate interplay between the immune system and skeletal muscles in Duchenne muscular dystrophy (DMD), as well as during regular muscle regeneration. While immune cell infiltration into skeletal muscles stands out as a prominent feature in the disease pathophysiology, a myriad of secondary defects involving metabolic and inflammatory pathways persist, with the key players yet to be fully elucidated. Steroids, currently the sole effective therapy for delaying onset and symptom control, come with adverse side effects, limiting their widespread use. Preliminary evidence spotlighting the distinctive features of T cell profiling in DMD prompts the immuno-characterization of circulating cells. A molecular analysis of their transcriptome and secretome holds the promise of identifying a subpopulation of cells suitable as disease biomarkers. Furthermore, it provides a gateway to unraveling new pathological pathways and pinpointing potential therapeutic targets. Simultaneously, the last decade has witnessed the emergence of novel approaches. The development and equilibrium of both innate and adaptive immune systems are intricately linked to the gut microbiota. Modulating microbiota-derived metabolites could potentially exacerbate muscle damage through immune system activation. Concurrently, genome sequencing has conferred clinical utility for rare disease diagnosis since innovative methodologies have been deployed to interpret the functional consequences of genomic variations. Despite numerous genes falling short as clinical targets for MD, the exploration of Tdark genes holds promise for unearthing novel and uncharted therapeutic insights. In the quest to expedite the translation of fundamental knowledge into clinical applications, the identification of novel biomarkers and disease targets is paramount. This initiative not only advances our understanding but also paves the way for the design of innovative therapeutic strategies, contributing to enhanced care for individuals grappling with these incapacitating diseases.

First person – Sheeza Mughal

First person – Mohamadamin Forouzandehmehr

First person – Eli Matsell

First person – Xiumei He

First person – Lauren Brilli Skvarca and Hwa Han

First person – Susan M. Motch Perrine and Meng Wu

First person – Vidur Sabharwal

First person – Samuele Metti

First person – Tak Shun Fung

First person – Emilie Auxerre-Plantié and Tanja Nielsen

First person – Emily D. McParland and T. Amber Butcher

First person – Andrew Porter

First person – Thomas Blake

Taurine activates the AKT–mTOR axis to restore muscle mass and contractile strength in human 3D in vitro models of steroid myopathy

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Treating Duchenne Muscular Dystrophy: The Promise of Stem Cells, Artificial Intelligence, and Multi-Omics

Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review

in vivo-like Scaffold-free 3D in vitro Models of Muscular Dystrophies: The Case for Anchored Cell Sheet Engineering in Personalized Medicine

Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice

Abstract 157: Atherosclerosis Is A Smooth Muscle Cell-driven Tumor-like Disease

Revealing myopathy spectrum: integrating transcriptional and clinical features of human skeletal muscles with varying health conditions